<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE GlossaryTerm >
<GlossaryTerm id="CDR0000560639"><TermName>yttrium Y 90 DOTA monoclonal antibody HuAFP31</TermName><TermPronunciation>(IH-tree-um … MAH-noh-KLOH-nul AN-tee-BAH-dee …)</TermPronunciation><TermDefinition><DefinitionText>A substance being studied in the treatment of liver cancer. HuAFP31 is a monoclonal antibody that can bind to tumor cells that make a protein called alpha fetoprotein (AFP). It is linked to a radioactive substance called yttrium Y 90, which may help kill the cancer cells. Yttrium Y 90 DOTA monoclonal antibody HuAFP31 is a type of radioimmunoconjugate.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000721068" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;yttrium Y 90 DOTA monoclonal antibody HuAFP31&quot;" language="en" id="_3"/><MediaLink ref="CDR0000721067" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;anticuerpo monoclonal HuAFP31 con itrio 90 DOTA&quot;" language="es" id="_4"/><SpanishTermName>anticuerpo monoclonal HuAFP31 con itrio 90 DOTA</SpanishTermName><SpanishTermDefinition><DefinitionText>Sustancia en estudio para el tratamiento de cáncer de hígado. HuAFP31 es un anticuerpo monoclonal que se puede unir a células tumorales que elaboran una proteína que se llama alfaproteína (AFP). Se la enlaza con una sustancia radiactiva que se llama itrio (Y 90), que puede ayudar a destruir las células cancerosas. El anticuerpo monoclonal HuAFP31 con itrio Y 90 DOTA es un tipo de radioinmunoconjugado.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2008-03-10</DateFirstPublished><DateLastModified>2010-04-30</DateLastModified></GlossaryTerm>
